A retrospective study leveraging 2-3 years of data found long-term HbA1c control was a greater predictor of COVID-19 severity than a single, contemporary HbA1c measurement as other studies have examined.
The latest review from the International Osteoporosis Foundation is a 14-page document with more than 100 references outlining current data related to the pathophysiological links between vascular calcification and bone loss.
New research from McGill University investigators details the risk-benefit ratio of antiglycemic agents, including SGLT2 inhibitors, GLP-1RAs, and DPP-4i, on cardiovascular risk reduction among patients with diabetes.
Data from the TRANSLATE-HF program suggests optimal prescription of SGLT2 inhibitors among hospitalized patients could have a significant impact on the risk of death and hospital readmission in the next year.
Data from the CLICK trial presented at Kidney Week 2021 demonstrates chlorthalidone reduced systolic blood pressure by 11 mmHg over a 12-week treatment period among a patient population with stage 4 CKD and uncontrolled hypertension.
Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial.
Using the Steno Type 1 Risk Engine, a team from Denmark conducted a study suggesting SGLT2 inhibition could lower risk of cardiovascular disease and end-stage kidney disease in patients with type 1 diabetes.